Somatic CRISPR editing of Msh3 reduces Huntington's disease pathology in mouse model
A preprint reports that in vivo CRISPR editing targeting the mismatch repair gene Msh3 slowed somatic CAG repeat expansion and mitigated disease pathology in a Huntington's disease mouse model.
A preprint posted to bioRxiv on 10 June 2026 describes a somatic gene-editing strategy for Huntington's disease (HD), a fatal autosomal dominant neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in exon 1 of the Huntingtin gene (HTT). Beyond the inherited germline expansion, progressive somatic CAG repeat expansion — particularly in neurons — is now understood to accelerate clinical onset, and the mismatch repair protein MSH3 has emerged as a principal driver of this somatic instability.
The authors used CRISPR-Cas9 to target Msh3 somatically in HD mouse models, aiming to slow ongoing repeat expansion rather than correct the germline mutation itself. The study examined the impact of editing at different disease stages, offering insight into whether intervening earlier or later in the disease process produces meaningfully different outcomes at the pathological level. Results reported in the preprint indicate that somatic Msh3 editing mitigated HD-associated pathology, consistent with the hypothesis that reducing somatic expansion is a viable therapeutic strategy.
MSH3 is supported as a therapeutic target by human genetic data: common variants at the MSH3 locus are associated with age of HD onset in genome-wide association studies. This preprint has not yet undergone peer review; methodology, effect sizes, and translational conclusions should be interpreted accordingly.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Huntington's disease is a serious inherited condition caused by a specific change — called a CAG repeat expansion — in a gene called Huntingtin. Researchers already know that this expansion can grow larger over time within the cells of the body, and that this growth may be linked to when symptoms begin.
A protein called MSH3 appears to drive this ongoing expansion. Scientists have now used a gene-editing technique called CRISPR to reduce MSH3 activity in mice with Huntington's disease. According to this early study, doing so slowed the expansion and reduced signs of disease in the animals.
This is a preprint — it has not yet been formally checked by other scientists in the peer-review process. It is also an animal study, and results in mice do not always translate to people. Much more research would be needed before this approach could be considered for use in humans.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary sourcePreprint bioRxiv (Cold Spring Harbor Laboratory) · 2026-06-10Somatic CRISPR editing of Msh3 mitigates Huntington's disease pathology in mice